Compare ES & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ES | INSM |
|---|---|---|
| Founded | 1927 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0B | 22.4B |
| IPO Year | 1994 | 2000 |
| Metric | ES | INSM |
|---|---|---|
| Price | $71.23 | $142.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 24 |
| Target Price | $72.29 | ★ $194.18 |
| AVG Volume (30 Days) | 2.8M | ★ 3.9M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | ★ 4.46% | N/A |
| EPS Growth | ★ 100.88 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $13,547,244,000.00 | N/A |
| Revenue This Year | N/A | $206.90 |
| Revenue Next Year | $6.81 | $60.68 |
| P/E Ratio | $40.38 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $62.72 | $90.39 |
| 52 Week High | $76.57 | $212.75 |
| Indicator | ES | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 74.43 |
| Support Level | $70.62 | $135.73 |
| Resistance Level | $71.41 | $142.90 |
| Average True Range (ATR) | 1.28 | 7.04 |
| MACD | 0.02 | 3.18 |
| Stochastic Oscillator | 56.26 | 83.03 |
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electricity and gas distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. It sold Aquarion in 2026. The company exited most of its unregulated businesses in 2006.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.